Table 4.
Estimation of treatment effects between second − line drugs: Treatment effect model with inverse probability weighting and regression adjustment
ATE (95% CI)
|
|||||
|---|---|---|---|---|---|
| Treatment | SU | TZD | DPP4i | SGLT2i | |
|
RR (95% CI)
|
ITT | ||||
| SU | Ref. | − 0.004 (− 0.023, 0.014) | − 0.046 (− 0.059, − 0.034) | − 0.142 (− 0.167, − 0.116) | |
| TZD | 0.98 (0.87, 1.08) | Ref. | − 0.042 (− 0.063, − 0.021) | − 0.137 (− 0.168, − 0.106) | |
| DPP4i | 0.74 (0.68, 0.81) | 0.76 (0.66, 0.86) | Ref. | − 0.095 (− 0.122, − 0.068) | |
| SGLT2i | 0.21 (0.07, 0.35) | 0.21 (0.07, 0.36) | 0.28 (0.09, 0.47) | Ref. | |
| PPA | |||||
| SU | Ref. | − 0.007 (− 0.030, 0.016) | − 0.055 (− 0.071, − 0.039) | − 0.177 (− 0.200, − 0.154) | |
| TZD | 0.96 (0.85, 1.08) | Ref. | − 0.074 (− 0.021, − 0.055) | − 0.201 (− 0.139, − 0.055) | |
| DPP4i | 0.73 (0.65, 0.80) | 0.75 (0.64, 0.87) | Ref. | − 0.149 (− 0.096, − 0.055) | |
| SGLT2i | 0.12 (0.01, 0.23) | 0.12 (0.01, 0.24) | 0.16 (0.01, 0.32) | Ref. | |
| Modified − ITT | |||||
| SU | Ref. | − 0.004 (− 0.023, 0.014) | − 0.046 (− 0.059, − 0.034) | − 0.142 (− 0.167, − 0.116) | |
| TZD | 0.98 (0.87, 1.08) | Ref. | − 0.042 (− 0.063, − 0.021) | − 0.137 (− 0.168, − 0.106) | |
| DPP4i | 0.74 (0.68, 0.81) | 0.76 (0.66, 0.86) | Ref. | − 0.095 (− 0.122, − 0.068) | |
| SGLT2i | 0.21 (0.07, 0.35) | 0.21 (0.07, 0.36) | 0.28 (0.09, 0.47) | Ref. | |
ATE: Average treatment effect; CI: Confidence interval; DPP4i: Dipeptidyl peptidase-4 inhibitors; ITT: Intention-to-treat; PPA: Per-protocol analysis; Ref.: Reference; RR: Relative risk; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; SU: Sulfonylureas; TZD: Thiazolidinediones